Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum
Open Access
- 16 November 2007
- journal article
- Published by Springer Nature in Malaria Journal
- Vol. 6 (1), 153
- https://doi.org/10.1186/1475-2875-6-153
Abstract
In malaria endemic areas children may recover from malaria after chemotherapy in spite of harbouring genotypically drug-resistant Plasmodium falciparum. This phenomenon suggests that there is a synergy between drug treatment and acquired immunity. This hypothesis was examined in an area of moderately intense transmission of P. falciparum in Tanzania during a drug trail with sulphadoxine-pyrimethamine (SP) or amodiaquine (AQ). One hundred children with uncomplicated malaria were treated with either SP or AQ and followed for 28 days. Mutations in parasite genes related to SP and AQ-resistance as well as human sickle cell trait and alpha-thalassaemia were determined using PCR and sequence-specific oligonucleotide probes and enzyme-linked immunosorbent assay (SSOP-ELISA), and IgG antibody responses to a panel of P. falciparum antigens were assessed and related to treatment outcome. Parasitological or clinical treatment failure (TF) was observed in 68% and 38% of children receiving SP or AQ, respectively. In those with adequate clinical and parasitological response (ACPR) compared to children with TF, and for both treatment regimens, prevalence and levels of anti-Glutamate-rich Protein (GLURP)-specific IgG antibodies were significantly higher (P < 0.001), while prevalence of parasite haplotypes associated with SP and AQ resistance was lower (P = 0.02 and P = 0.07, respectively). Interestingly, anti-GLURP-IgG antibodies were more strongly associated with treatment outcome than parasite resistant haplotypes, while the IgG responses to none of the other 11 malaria antigens were not significantly associated with ACPR. These findings suggest that GLURP-specific IgG antibodies in this setting contribute to clearance of drug-resistant infections and support the hypothesis that acquired immunity enhances the clinical efficacy of drug therapy. The results should be confirmed in larger scale with greater sample size and with variation in transmission intensity.Keywords
This publication has 46 references indexed in Scilit:
- Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyte-related genetic factors in Plasmodium falciparum malariaInfection, Genetics and Evolution, 2007
- Limited Cross-Reactivity among Domains of the Plasmodium falciparum Clone 3D7 Erythrocyte Membrane Protein 1 FamilyInfection and Immunity, 2006
- Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidateVaccine, 2006
- Immunoglobulin G Antibodies to Merozoite Surface Antigens Are Associated with Recovery from Chloroquine-ResistantPlasmodium falciparumin Gambian ChildrenInfection and Immunity, 2006
- Plasmodium falciparum Associated with Severe Childhood Malaria Preferentially Expresses PfEMP1 Encoded by Group A var GenesThe Journal of Experimental Medicine, 2004
- Association between Protection against Clinical Malaria and Antibodies to Merozoite Surface Antigens in an Area of Hyperendemicity in Myanmar: Complementarity between Responses to Merozoite Surface Protein 3 and the 220-Kilodalton Glutamate-Rich ProteinInfection and Immunity, 2004
- Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiologyCurrent Opinion in Infectious Diseases, 2003
- Increased Efficacy of Sulfadoxine‐Pyrimethamine in the Treatment of Uncomplicated Falciparum Malaria among Children with Sickle Cell Trait in Western KenyaThe Journal of Infectious Diseases, 2002
- Chloroquine‐Resistant MalariaThe Journal of Infectious Diseases, 2001
- Malaria: drug use and the immune responseParasitology, 1992